FDA
-
-
-
-
-
-
-
Bernstein SocGen Group Reiterates Market Perform Rating on BioNTech (BNTX)
-
-
-
-
-
-
-
FDA intends to put most serious warning on COVID vaccines, CNN reports
-
-
-
-
-
-
-
Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula
-
-
-
-
-
-
-
As FDA delays Novavax' COVID vaccine approval, patients fight back
-
-
-
-
-
-
-
BioNTech SE (BNTX): FDA has placed partial clinical hold on two-stage, open-label, randomized Phase 3 trial, PRESERVE-003
-
-
-
-
-
-
-
BioNTech (BNTX) Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma
-
-
-
-
-
-
-
WuXi Biologics Reports Solid 2023 Annual Results
-
331,403 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

